Ovarian hyperstimulation syndrome (OHSS) is the most serious complication of controlled ovarian hyperstimulation (COH). In its most severe form, which occurs in 0.3% to 5.0% of cycles (1) , it is associated with significant morbidity and can be life threatening. The pathophysiology is unclear and specific therapeutic management is not available. The syndrome is associated with ovarian enlargement and an increase in capillary permeability (2) , which leads to an extensive, predominantly intra-abdominal accumulation of fluid. The resultant depletion of intravascular fluid volume leads, in turn, to secondary hemodynamic consequences, particularly increased coagulation and prerenal failure. The effect of excessive gonadotropins on ovarian tissue accounts for the ovarian enlargement, whereas the cause of the increased capillary permeability and subsequent third space accumulation is unknown.
Although the pathophysiology of OHSS is unknown, it seems probable that the release of a vasoactive substance secreted by the ovaries under human chorionic gonadotropin (hCG) stimulation plays a key role in triggering this syndrome (2, 3) . Several substances have been proposed as the intermediary responsible for the increase in capillary permeability. However, exaggerated folliculogenesis (4) and the interaction between the immune and reproductive systems (5) are the pathogenetic forerunners. Physiological angiogenesis is infrequent; when it does occur, it seems to be restricted to females (6) . Angiogenesis is an essential component of both follicular and luteal phases of the ovarian cycle (7) but is particularly aggressive in early luteogenesis. Vascular endothelial growth factor (VEGF) has emerged as one of the most important inducers of angiogenesis in the ovary. During follicular growth, the dominant follicle develops a complex vascular network within the thecal layer; VEGF-dependent angiogenesis is essential for corpus luteum development (8). Phillips et al. (9) described a temporal and spatial relationship between VEGF mRNA expression and physiological proliferation of blood vessels in the ovarian corpus luteum.
Studies on VEGF in OHSS patients have shown that it may be responsible for the increase in vascular permeability seen in this syndrome (10) . Serum VEGF levels were significantly higher on day 14 after hCG administration in a group who developed severe OHSS, compared with those who did not (11) . Similarly, high VEGF plasma levels have been demonstrated in patients with severe OHSS, which dropped significantly with clinical improvement (12) . Furthermore, the kinetics of VEGF in the plasma of patients who developed OHSS was closely correlated with the clinical course of the syndrome and with certain biological characteristics. McClure et al. (10) found that VEGF was the major capillary permeability factor in OHSS ascites, as addition of specific antibodies against VEGF neutralized 70% of capillary permeability activity.
There would appear to be no doubt that VEGF is an essential component of the physiological angiogenesis that accompanies follicular growth. In contrast to the development of one follicle in a natural cycle, multiple follicles are associated with an excess of VEGF, which can overspill the ovarian capillary bed and exert its effects in the peritoneal cavity. In addition to inducing angiogenesis and producing proliferation of endothelial cells during corpus luteum growth, VEGF induces vascular permeability. Endothelial cell permeability induced by the follicular fluid of patients undergoing assisted reproduction therapy was highly correlated with oocyte number. This effect was almost completely reversed by the addition of anti-VEGF antibody (13) . Previously, Goldsman et al. (2) had reported an augmentation in the permeability rate of both follicular fluid and peritoneal fluid from patients undergoing COH who responded with an increasing number of oocytes compared with controls. Therefore, it is likely that VEGF is the follicular fluid factor responsible for the increased vascular permeability, and hence morbidity, in OHSS (Fig. 1 ).
Only a minority of patients with ovarian hyperstimula-
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tion, however, go on to develop the syndrome. It is possible that some patients can deal endogenously with the excess levels of VEGF better than others. Some of the variations in symptoms attributable to VEGF levels between women may be explained by variations in the level of free and sequestered VEGF.
The objective of this study was to determine if the serum of patients who developed OHSS differed in its ability to bind VEGF in vitro when compared with the serum of patients who did not develop OHSS, despite processing large numbers of oocytes for oocyte retrieval.
MATERIALS AND METHODS
Patient Selection and Study Design
This study was performed between August 1998 to July 2000. Serum was collected prospectively from 218 women who were undergoing in vitro fertilization (IVF) at the time of oocyte retrieval. Subsequently five women (2%) were identified who developed severe OHSS (14) (Group 1). Five control patients who did not develop OHSS were identified from the cohort tested (Group 2). All of the women had more than 15 oocytes and were matched for age and diagnosis.
In addition, a chart review identified two women who had been hyperstimulated during a previous cycle of IVF, one of whom had developed critical OHSS and one who had remained asymptomatic. Consent was obtained and serum was collected on three occasions during a natural cycle from both women (day 1 to 5, periovulatory and midluteal).
All clinical procedures were performed at the Regional Fertility Centre Royal Maternity Hospital, Belfast. Ethical approval for the study was obtained from the Queen's University Belfast research ethics committee.
Assisted Reproduction Stimulation Procedure
All patients underwent a standard stimulation protocol with pituitary down-regulation by gonadotrophin-releasing hormone agonist analogue (GnRH-a) (Synarel, Searle, High Wycombe, UK) commenced in the midluteal phase and administered nasally until the ovulatory hCG injection. Ovulation induction was with human menopausal gonadotrophin (hMG) (Menogon, Ferring, Langley, UK) or recombinant follicle stimulating hormone (rFSH) (Gonal F, Serono Pharmaceuticals, Feltham, UK; or Puregon, Organon Laboratories Ltd., Cambridge, UK) in a high, standard, or low dose regimen.
The women were scanned on day 11 of stimulation to determine the degree of ovarian response. Those with fewer than four follicles Ͼ18 mm in diameter had their cycle abandoned. The remainder received an hCG (Profasi, Serono) injection of 10,000 IU to induce final oocyte maturation. At 34 to 36 hours after hCG administration, all ovarian follicles were aspirated transvaginally under ultrasound control. The women received Rapifen (Janssen-Cilag, HighWycombe, UK) intravenously as necessary for pain relief. Immediately before commencing oocyte retrieval, a sample of peripheral blood was taken. The blood was allowed to clot, then was refrigerated and centrifuged before the serum was withdrawn. The serum samples were stored at Ϫ70°C until required for analysis. Women thought to be at significant risk of OHSS (guideline: total oocyte number Ͼ15) were offered the option of embryo freezing rather than fresh embryo transfer.
Column Chromatography
Serum samples were applied sequentially to a sephadex G-150 gel filtration column measuring 1.0 ϫ 60 cm. The column was eluted with phosphate buffer, 0.04 M, pH 7.4, which contained bovine serum albumin (BSA, 0.1% Sigma RIA grade). A flow rate of 4 mL/hour was used. Chromatography was performed at 4°C and 500 L fractions were collected.
Serum (175 L) from five women who developed severe OHSS and five case-matched controls was incubated with 125 I-VEGF 165 (Amersham Pharmacia Biotech, UK Ltd.) (25 L) for 2 hours at room temperature. The samples (200 L) were applied to the column in turn. Fraction radioactivity was analysed by a gamma counter (Wallac 1277 Gammamaster, automatic gamma counter).
The 125 I-VEGF 165 applied to the column eluted in two peaks centered on fractions 18 Ϯ 2 and 39 Ϯ 2. The first peak was a high-molecular-weight compound (Ͼ300 kDa) representing "bound" 125 I-VEGF 165 . The second peak was understood to be unbound 125 I-VEGF 165 because the elution pattern was identical to that of neat 125 I-VEGF 165 . The percentage of 125 I-VEGF 165 bound in each group was calculated and compared.
In addition, during a natural cycle, the serum from the woman who had 17 oocytes collected during a cycle of IVF and developed critical OHSS was subjected to analysis, as was the serum from the woman who had 41 oocytes collected and remained asymptomatic. In both cases the periovulatory blood sample was prepared and subjected to analysis by column chromatography. Recovery from the column was Ͼ90%.
Statistical Analysis
All data are presented as median (interquartile range). Due to the non-Gaussian distribution of the data, differences between the two groups were assessed by the Mann-Whitney U-test. All analyses were performed using the Statistica package (Statsoft Version 5.1, Hamburg, Germany). The level of significance was set at P Յ.05.
RESULTS
There was no statistically significant difference between the two groups with regards to age, duration of infertility, dose of gonadotropins, and number of oocytes collected.
In all of the column chromatography studies on serum from cases with or without OHSS there were two peaks of radioactivity centered on fractions 18Ϯ2 and 39Ϯ2, representing "bound" and "unbound" VEGF. In the "natural cycle" column chromatography study, the serum from the woman who produced 41 oocytes but remained well bound significantly more of the 125 I-VEGF 165 (37.4% vs. 13.75%) than that of the woman with a history of 17 oocytes and critical OHSS. This difference was statistically significant (P Ͻ.001), Mann-Whitney U-test (Fig. 2) .
DISCUSSION
This is the first time that it has been suggested that some patients are inherently protected from developing OHSS.
The putative factor would appear to be a high-molecularweight serum protein. This is particularly relevant as it may offer the possibility of supplementation of the factor as a therapy for OHSS.
With rare exceptions, OHSS is an iatrogenic condition that occurs in otherwise healthy young women. The pathophysiology is still unclear. Further, there are no specific therapeutic measures. Therefore, the most effective management is its accurate prediction and active prevention. Surprisingly, the introduction of estradiol measurement and ultrasonography has proved to be of limited value in this respect. This lends support to the concept that the degree of ovarian stimulation may not be the only factor in the pathogenesis of the condition.
In a natural menstrual cycle, ovarian angiogenesis is normally restricted to a single follicle and OHSS does not occur. In cases of ovarian hyperstimulation, multiple follicles are associated with supraphysiologic angiogenic activity. The substantial increase in the number of corpora lutea seen in ovarian hyperstimulation compared with that of a natural cycle may result in unnaturally high levels of circulating VEGF. Accumulated data would suggest that the possible mechanism of increased capillary permeability found in OHSS might be due to the systemic effect of VEGF and not its origin in the ovary (15) . Therefore, VEGF may overspill the ovarian capillary bed and exert its effects systemically.
The biological relationship between VEGF and OHSS has been well established. Indeed, the central role of VEGF as the mediator involved in OHSS pathogenesis is not in dispute. However, other factors must be involved. If "oocyte number" correlates with VEGF and VEGF is the agent responsible for the development of OHSS, why is it that only a minority of patients with ovarian hyperstimulation develop the syndrome?
Several studies have demonstrated that, although VEGF levels are elevated in patients with hyperstimulated ovaries (16) , there is no statistically significant difference between those with hyperstimulated ovaries who subsequently de-
T A B L E 1
Comparison between the characteristics of the group who developed OHSS and the group who remained symptom free. 
F I G U R E 2
Column chromatography of "natural cycle" serum in two women with and without a history of OHSS in a previous cycle of COH for IVF. Solid line ϭ 41 oocytes, no-OHSS. Dotted line ϭ 17 oocytes, critical OHSS.
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velop OHSS and those who do not (17) (18) (19) (20) . Other factors must interfere with the systemic effects of VEGF. Ludwig et al. (21) demonstrated a 100-fold higher concentration of total circulating VEGF than the concentration of free VEGF. Furthermore, patients who developed OHSS had significantly more free VEGF although no such difference existed with respect to total circulating VEGF. This work is in agreement with our hypothesis that patients who are protected from the development of OHSS are able to sequester more of the free VEGF.
The prime target cells for VEGF are the endothelial cells (22) . Therefore, a binding protein for VEGF may be present in patients' serum in differing amounts. The binding protein acts as a removing and inactivating protein, and the relationship between the level of the binding protein and free VEGF determines whether a patient develops OHSS.
Binding proteins for growth factors fall into two categories: [1] membrane-bound high affinity binding proteins, or receptors, and [2] soluble binding proteins secreted from cells. Soluble binding proteins may act to inactivate the biological activity of the protein, in this case VEGF. These results would be in keeping with the presence of a binding protein in patients' serum that inactivates the VEGF, variations in the level offering different degrees of protection.
This work is novel in that it suggests that it is how individuals deal with the VEGF that determines whether they develop the syndrome. The serum from the no-OHSS group of patients sequestered significantly more of the radioactive VEGF than did the OHSS group.
Despite the small numbers included in this study, the results strongly support the concept that patients' serum may contain a VEGF removing and inactivating protein whose activity varies between individuals. Some of the variation in symptoms attributable to VEGF levels between women may be explained by variations in the levels of free and bound VEGF receptor proteins. Apparently, to date, no studies exploring these relationships have been published. Work is ongoing to determine the nature of this VEGF-binding protein.
